UPDATE 1-Regulators flag possible birth defect link to GSK's HIV drug
May 18, 2018 at 13:23 PM EDT
LONDON, May 18 (Reuters) - U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.